Anthony Lebiedzinski

Ivan Feinseth

Douglas Lane

Linda Bolton-Weiser

Song Xue

- **USANA Health Sciences** reported a **third-quarter loss** with **earnings per share of 36 cents**, missing forecasts and causing its stock to fall **10-11%**.  **[896264_30bd056fc3a44dd2aecc818f29f07d8d]** 
- The company attributed the disappointing results to **slower-than-expected sales growth** and a decline in **active customer counts**, particularly in its direct-to-consumer segment, Hiya.  **[896264_30bd056fc3a44dd2aecc818f29f07d8d]** 
- Despite a modest revenue increase to **around $214 million**, **operating profits dropped sharply**, leading to a revised outlook for **full-year earnings below previous guidance** and sales near the lower end of its forecast.  **[896264_30bd056fc3a44dd2aecc818f29f07d8d]** 
- Investor sentiment has turned **cautious**, reflected in a lowered **price-to-earnings ratio from 10 to 8** in 2025, though the company maintains **strong financial health** with a current ratio of **2.15** and a debt-to-equity ratio of **0.04**.  **[896264_30bd056fc3a44dd2aecc818f29f07d8d]**

USANA Health Sciences Reports Q3 Loss, Lowers Full-Year Guidance

- USANA Health Sciences reported preliminary **Q3 2025 net sales of $214 million**, an increase from **$200 million** in Q3 2024, but posted a **net loss of ($6.5) million** and **diluted EPS of ($0.36)** for Q3 2025, compared to net earnings of **$10.6 million** and diluted EPS of **$0.56** in Q3 2024.  **[896264_0000896264-25-000210_exhibit991q32025earningsan.htm:0]** **[896264_0000896264-25-000210_exhibit991q32025earningsan.htm:1]** **[896264_0000896264-25-000210_exhibit991q32025earningsan.htm:3]** 
- The company attributed the results below expectations to softer-than-anticipated sales and Brand Partner productivity during the rollout of an enhanced compensation plan, lower customer acquisition rates for its Hiya direct-to-consumer business, and a significantly higher effective income tax rate of **471%** for the quarter.  **[896264_0000896264-25-000210_exhibit991q32025earningsan.htm:0]** **[896264_0000896264-25-000210_exhibit991q32025earningsan.htm:1]** 
- As a result, USANA expects full-year sales to be at or near the **lower end of its previously issued outlook range**, and full-year earnings per share to be **below the range**.  **[896264_0000896264-25-000210_exhibit991q32025earningsan.htm:0]**

USANA Health Sciences Announces Preliminary Q3 2025 Results and Updates Full-Year Outlook

- USANA Health Sciences reported preliminary **Q3 2025 net sales of approximately $214 million**, an increase from $200 million in the prior-year period.  **[896264_5484503905c64f16971cecd5beabdb4b_0]** **[896264_5484503905c64f16971cecd5beabdb4b_1]** 
- However, **profitability significantly declined**, with preliminary **Q3 2025 earnings from operations at $1.2 million** (0.6% of net sales) compared to $15.6 million in Q3 2024, and a **diluted EPS of ($0.36)** versus $0.56 in Q3 2024.  **[896264_5484503905c64f16971cecd5beabdb4b_0]** **[896264_5484503905c64f16971cecd5beabdb4b_1]** 
- This underperformance was primarily driven by **softer-than-expected sales and Brand Partner productivity** during the rollout of an enhanced compensation plan, and lower customer acquisition rates for the Hiya direct-to-consumer business.  **[896264_5484503905c64f16971cecd5beabdb4b_0]** 
- The company also reported a **471% effective income tax rate** for Q3 2025, significantly higher than 43% in Q3 2024, due to a change in the estimated annual effective income tax rate.  **[896264_5484503905c64f16971cecd5beabdb4b_1]** **[896264_5484503905c64f16971cecd5beabdb4b_0]** 
- As a result, USANA expects **full-year sales to be at or near the lower end of its previous outlook range and earnings per share to be below the range**.  **[896264_5484503905c64f16971cecd5beabdb4b_1]**

USANA HEALTH SCIENCES (USNA)